Lividomycinの再治療重症肺結核患者に対する治療効果の研究

概要

論文の詳細を見る
Therapeutic effects of Lividomycin (LVM) for eighty eight retreatment cases of pulmonary tuberculosis with positive tubercle bacilli were studied. LVM was principally added to the previous regimens which had been used before this trial, and this drug was used in place of SM, KM, CPM and VM. LVM was administered in the dose of 1 g intramuscularly three times a week in the case with body weight more than 50 kg and 0.75 g in the case with less than 49 kg. Those cases were div ided into two groups, namely the fifty two cases of A group in which sensitive drugs or unused drugs were combined and the thirty six cases of B group in which only resistant drugs or previously used drugs were used. The background factors between both groups were nearly equal.